~~<i id='6020577311'><strike id='6020577311'><tt id='6020577311'><pre id='6020577311'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

focus

author：Wikipedia 2025-09-30 10:48:19 - browse：97

A European regulatory panel has recommended against approval of a lung cancer drug made by Mirati Therapeutics, the company said Friday.

Mirati said it will appeal the negative opinion of the drug, called Krazati, issued by a committee of the European Medicines Agency that met this week. But for now, the adverse decision is likely to be adopted by European regulators and prevent the company from marketing the pill in Europe.

Krazati works by blocking a specific type of KRAS alteration called G12C, found in approximately 13% of lung tumors.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： FDA panel to weigh safety of artificial wombs for preterm births

entertainment

leisure time

hotspot

Wikipedia

focus

entertainment

AdobeArecentstudybytheAssociationofAmericanMedicalCollegesprojects ashortageofbetween17,800and48,000

WSS

Startup Neumora takes a novel depression drug to Phase 3

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

The struggle to figure out which patients 'deserve' Wegovy

Group opposing PBM reform sets lobbying record

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Why hospitals are withdrawing from US News rankings

knowledge

focus

entertainment

Malaria cases in Florida and Texas: Here’s what you need to know

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Senate bill would ban some hospital facility fees

Sports medicine is finally prioritizing gender equality

Fed up with FDA, ALS advocates consider a take

United colonoscopy coverage change 'may cost lives,' doctors say

Akili changes sales model for its ADHD video game treatment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Eli Lilly CEO gives to Mike Pence presidential super PAC

leisure time

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

How the messy conversation about Dolly changed bioethics

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

David Liu startup to focus on CRISPR delivery

Sanders adds drug shortage policies to pandemic preparedness bill

ARCH Venture Partners tops STAT's 2023 biotech VC rankings

hotspot

Wikipedia

focus

entertainment